Kiyatec

Executive Summary

Kiyatec is a US-based biotechnology company pioneering functional precision oncology through its proprietary 3D Predict platform, which uses ex vivo 3D cell cultures to predict patient-specific responses to cancer therapies before treatment initiation. By mimicking tumor microenvironments, the platform provides oncologists with actionable insights to optimize therapeutic decisions, potentially improving outcomes and reducing ineffective treatments. Founded in 2005 and headquartered in Greenville, South Carolina, the company operates at the intersection of diagnostics and personalized medicine, targeting a significant unmet need in oncology. The 3D Predict platform aims to shift from traditional genomic profiling to functional testing, offering a more direct measure of drug sensitivity. With its long-standing presence and niche focus, Kiyatec is positioned to capture value in the growing precision oncology market, though it remains privately held and has not disclosed funding or valuation. The company's technology has the potential to reduce healthcare costs by avoiding ineffective therapies and enabling more efficient treatment pathways.

Upcoming Catalysts (preview)

• Q3 2026Publication of Validation Study in Peer-Reviewed Journal70% success
• Q4 2026Pharma Partnership for Drug Sensitivity Testing50% success
• Q1 2027CLIA Certification Expansion for 3D Predict Platform60% success